Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
Charles B NguyenMelissa A ReimersChamila PereraWassim AbidaJonathan ChouFelix Y FengEmmanuel S AntonarakisRana R McKayRussell K PachynskiJingsong ZhangZachery R ReichertPhillip L PalmbosMegan E V CaramUlka N VaishampayanElisabeth I HeathAlexander C HopkinsMarcin P CieslikYi-Mi WuDan R RobinsonVeerabhadran BaladandayuthapaniArul M ChinnaiyanAjjai Shivaram AlvaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
There was minimal activity with ICI therapy in patients with CDK12-altered mCRPC.